#bigdataforbloodcancer
The HARMONY Alliance is enabling better and faster treatment for blood cancer patients

HARMONY: 53 Partners, Patient Cluster of 7 European Patient Organizations, 43 Associated Members. Budget: Euro 40 million. Period: January 2017 until December 2021. 

HARMONY PLUS: 39 Partners, 8 Associated Partners. Euro Budget: 11,8 million. Period: October 2020 until September 2023. 

HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. The HARMONY Alliance has received funding from IMI 2 Joint Undertaking and is listed for HARMONY under grant agreement No. 116026 and for HARMONY PLUS grant agreement No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.

Health Data

Life Sciences

Pharmaceutical

HARMONY Alliance | Public-Private Partnership for Big Data in Hematology

HARMONY Alliance | Public-Private Partnership for Big Data in Hematology's headquarters in The Hague, Netherlands

HARMONY Alliance | Public-Private Partnership for Big Data in Hematology

Org chart

Teams

Offices

Similar companies